LPL and cancer: In this study, we used drug-targeted MR and identified several newer nonstatin lipid-lowering agents, such as those targeting LPL, ANGPTL3, and LDLR, which were associated with increased human lifespans and decreased risks of several common cancers and cardiometabolic disorders.